Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis

Cancer Prevention Research

Volumn 3, Issue 3, 2010, Pages 359-370

  Camalier, Corinne E ^a,b   Young, Matthew R ^b   Bobe, Gerd ^b,d   Perella, Christine M ^c   Colburn, Nancy H ^b   Beck Jr , George R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 O TETRADECABOYLPHORBOL 13 ACETATE; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ACETIC ACID; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; PHOSPHATE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOOD INTAKE; GENE EXPRESSION; IN VITRO STUDY; MOUSE; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SUPPLEMENTATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; CYCLOOXYGENASE 2; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPIDERMIS; FEMALE; GENES, RAS; LUCIFERASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOPONTIN; PAPILLOMA; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS, DIETARY; PROTO-ONCOGENE PROTEINS C-FOS; SKIN NEOPLASMS; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 77949756762     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0068     Document Type: Article

References (63)

1. Newberne PM, Conner MW. Dietary modifiers of cancer. Prog Clin Biol Res 1988;259:105-29.
2. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.
3. Go VL, Wong DA, Wang Y, Butrum RR, Norman HA, Wilkerson L. Diet and cancer prevention: evidence-based medicine to genomic medicine. J Nutr 2004;134:3513-6S.
4. Holley RW, Kiernan JA. Control of the initiation of DNA synthesis in 3T3 cells: low-molecular weight nutrients. Proc Natl Acad Sci U S A 1974;71:2942-5.
5. Weber MJ, Edlin G. Phosphate transport, nucleotide pools, and ribonucleic acid synthesis in growing and in density-inhibited 3T3 cells. J Biol Chem 1971;246:1828-33.
6. Hilborn DA. Serum stimulation of phosphate uptake into 3T3 cells. J Cell Physiol 1976;87:111-21.
7. Rubin H, Sanui H. Complexes of inorganic pyrophosphate, orthophosphate, and calcium as stimulants of 3T3 cell multiplication. Proc Natl Acad Sci U S A 1977;74:5026-30.
8. Conrads KA, Yi M, Simpson KA, et al. A combined proteome and microarray investigation of inorganic phosphate-induced pre-osteoblast cells. Mol Cell Proteomics 2005;4:1284-96.
9. Beck GR, Jr., Moran E, Knecht N. Inorganic phosphate regulates multiple genes during osteoblast differentiation, including Nrf2. Exp Cell Res 2003;288:288-300.
10. Beck GR, Jr., Zerler B, Moran E. Phosphate is a specific signal for induction of osteopontin gene expression. Proc Natl Acad Sci U S A 2000;97:8352-7.
11. Conrads KA, Yu LR, Lucas DA, et al. Quantitative proteomic analysis of inorganic phosphate-induced murine MC3T3-1 osteoblast cells. Electrophoresis 2004;25:1342-52.
12. Beck GR, Jr., Knecht N. Osteopontin regulation by inorganic phosphate is ERK1/2-, protein kinase C-, and proteasome-dependent. J Biol Chem 2003;278:41921-9.
13. Chang SH, Yu KN, Lee YS, et al. Elevated inorganic phosphate stimulates Akt-ERK1/2-Mnk1 signaling in human lung cells. Am J Respir Cell Mol Biol 2006;35:528-39.
14. Bernstein LR, Colburn NH. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989;244:566-9.
15. Colburn NH, Former BF, Nelson KA, Yuspa SH. Tumour promoter induces anchorage independence irreversibly. Nature 1979;281:589-91.
16. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoterinduced transformation. Oncogene 2004;23:4466-76.
17. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cellproliferation and transformation. Biochim Biophys Acta 1991;1072:129-57.
18. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006;71:1397-421.
19. Gupta S, Mukhtar H. Chemoprevention of skin cancer: current status and future prospects. Cancer Metastasis Rev 2002;21:363-80.
20. Dong Z. Effects of food factors on signal transduction pathways. Biofactors 2000;12:17-28.
21. Denhardt DT, Mistretta D, Chambers AF, et al. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis 2003;20:77-84.
22. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-81.
23. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-74.
24. Matthews CP, Birkholz AM, Baker AR, et al. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res 2007;67:2430-8.
25. Slaga TJ, Budunova IV, Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. J Investig Dermatol Symp Proc 1996;1:151-6.
26. Malumbres M, Pellicer A. RAS pathways to cell cycle control and cell transformation. Front Biosci 1998;3:d887-912.
27. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
28. Mangues R, Seidman I, Gordon JW, Pellicer A. Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice. Oncogene 1992;7:2073-6.
29. Wasylyk C, Imler JL, Wasylyk B. Transforming but not immortalizing oncogenes activate the transcription factor PEA1. EMBO J 1988;7:2475-83.
30. Ise K, Nakamura K, Nakao K, et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000;19:2951-6.
31. Cunningham DD, Pardee AB. Transport changes rapidly initiated by serum addition to "contact inhibited" 3T3 cells. Proc Natl Acad Sci U S A 1969;64:1049-56.
32. Engstrom W, Zetterberg A. Phosphate and the regulation of DNA replication in normal and virus-transformed 3T3 cells. Biochem J 1983;214:695-702.
33. Shin SI, Freedman VH, Risser R, Pollack R. Tumorigenicity of virustransformed cells in nude mice is correlated specifically with anchorage independent growth in vitro. Proc Natl Acad Sci U S A 1975;72:4435-9.
34. Chang PL, Cao M, Hicks P. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis 2003;24:1749-58.
35. Meng Z, Camalier CE, Lucas DA, Veenstra TD, Beck GR, Jr., Conrads TP. Probing early growth response 1 interacting proteins at the active promoter in osteoblast cells using oligoprecipitation and mass spectrometry. J Proteome Res 2006;5:1931-9.
36. Bernstein LR, Bravo R, Colburn NH. 12-O-tetradecanoylphorbol-13- acetate-induced levels of AP-1 proteins: a 46-kDa protein immunoprecipitated by anti-fra-1 and induced in promotion-resistant but not promotion-sensitive JB6 cells. Mol Carcinog 1992;6:221-9.
37. Dong Z, Lavrovsky V, Colburn NH. Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis 1995;16:749-56.
38. Young MR, Nair R, Bucheimer N, et al. Transactivation of Fra-1 and consequent activation of AP-1 occur extracellular signal-regulated kinase dependently. Mol Cell Biol 2002;22:587-98.
39. Kovary K, Bravo R. Existence of different Fos/Jun complexes during the G0-to-G1 transition and during exponential growth in mouse fibroblasts: differential role of Fos proteins. Mol Cell Biol 1992;12:5015-23.
40. Piechaczyk M, Farras R. Regulation and function of JunB in cell proliferation. Biochem Soc Trans 2008;36:864-7.
41. Kang NJ, Lee KW, Kwon JY, et al. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling. Cancer Prev Res 2008;1:522-31.
42. Szczepanska-Konkel M, Yusufi AN, VanScoy M, Webster SK, Dousa TP. Phosphonocarboxylic acids as specific inhibitors of Na+-dependent transport of phosphate across renal brush border membrane. J Biol Chem 1986;261:6375-83.
43. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murine Nras gene is not essential for growth and development. Proc Natl Acad Sci U S A 1995;92:1709-13.
44. Diaz R, Lopez-Barcons L, Ahn D, et al. Complex effects of Ras protooncogenes in tumorigenesis. Carcinogenesis 2004;25:535-9.
45. Fotiadou PP, Takahashi C, Rajabi HN, Ewen ME. Wild-type NRas and KRas perform distinct functions during transformation. Mol Cell Biol 2007;27:6742-55.
46. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8.
47. Jin H, Xu CX, Lim HT, et al. High dietary inorganic phosphate increases lung tumorigenesis and alters Akt signaling. Am J Respir Crit Care Med 2009;179:59-68.
48. Reiss E, Canterbury JM, Bercovitz MA, Kaplan EL. The role of phosphate in the secretion of parathyroid hormone in man. J Clin Invest 1970;49:2146-9.
49. Calvo MS, Kumar R, Heath H. Persistently elevated parathyroid hormone secretion and action in young women after four weeks of ingesting high phosphorus, low calcium diets. J Clin Endocrinol Metab 1990;70:1334-40.
50. Errazahi A, Bouizar Z, Lieberherr M, Souil E, Rizk-Rabin M. Functional type I PTH/PTHrP receptor in freshly isolated newborn rat keratinocytes: identification by RT-PCR and immunohistochemistry. J Bone Miner Res 2003;18:737-50.
51. Sharpe GR, Dillon JP, Durham B, Gallagher JA, Fraser WD. Human keratinocytes express transcripts for three isoforms of parathyroid hormone-related protein (PTHrP), but not for the parathyroid hormone/ PTHrP receptor: effects of 1,25(OH)2 vitamin D3. Br J Dermatol 1998;138:944-51.
52. Duff MD, Mestre J, Maddali S, Yan ZP, Stapleton P, Daly JM. Analysis of gene expression in the tumor-associated macrophage. J Surg Res 2007;142:119-28.
53. Portale AA, Halloran BP, Murphy MM, Morris RC, Jr. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986;77:7-12.
54. Portale AA, Halloran BP, Morris RC, Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989;83:1494-9.
55. Kemi VE, Karkkainen MU, Lamberg-Allardt CJ. High phosphorus intakes acutely and negatively affect Ca and bone metabolism in a dose-dependent manner in healthy young females. Br J Nutr 2006; 96:545-52.
56. Nishida Y, Taketani Y, Yamanaka-Okumura H, et al. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 2006;70:2141-7.
57. Katsumata S, Masuyama R, Koshihara M, Matsuzaki H, Uehara M, Suzuki K. High phosphorus diet changes phosphorus metabolism regardless of PTH action in rats. Biosci Biotechnol Biochem 2004; 68:243-6.
58. Czarnogorski M, Woda CB, Schulkin J, Mulroney SE. Induction of a phosphate appetite in adult male and female rats. Exp Biol Med (Maywood) 2004;229:914-9.
59. Calvo MS. Dietary phosphorus, calcium metabolism and bone. J Nutr 1993;123:1627-33.
60. Huttunen MM, Tillman I, Viljakainen HT, et al. High dietary phosphate intake reduces bone strength in the growing rat skeleton. J Bone Miner Res 2007;22:83-92.
61. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial 2003;16:186-8.
62. Hsieh YH, Juliana MM, Hicks PH, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res 2006;66:7119-27.
63. McCarty MF. A moderately low phosphate intake may provide health benefits analogous to those conferred by UV light-a further advantage of vegan diets. Med Hypotheses 2003;61:543-60.